Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

OBJECTIVES: The objective of this study was to evaluate the cost-effectiveness of abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors as compared with rituximab in Finnish rheumatoid arthritis patients, who have previously been treated with TNF inhibitors. METHODS: A patient-level sim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Huoponen, Saara, Aaltonen, Kalle J., Viikinkoski, Jaana, Rutanen, Jarno, Relas, Heikki, Taimen, Kirsi, Puolakka, Kari, Nordström, Dan, Blom, Marja
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656352/
https://ncbi.nlm.nih.gov/pubmed/31339961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0220142
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados